Ronald J. Shebuski, PhD
President & CEO
Dr. Shebuski was hired as President of Cylerus in 2010, bringing extensive research and management experience in biotechnology development, including large pharmaceutical firms (Upjohn, SKF, Merck) as well as smaller companies. He has overall responsibility for day-to-day operations and manages consultants and contractors in the development of new drug formulations and the manufacture of the Company’s local drug delivery device.
Stephen R. Hanson, PhD
Founder & Board Chair
Cylerus technology is based on work from the laboratory of Dr. Stephen Hanson, former Chairman of Biomedical Engineering, Oregon Health & Sciences University (Portland OR). His studies over many years had led to the conclusion that preservation of graft patency would be best achieved by local, endoluminal delivery of an antiproliferative agent like sirolimus, an approach that is now the basis of Company’s technology platform and intellectual property.
Patrick J. Delehanty, MBA
Mr. Delehanty serves as the Company’s Chief Financial Officer. Mr. Delehanty has worked in various discovery research and financial positions at the Upjohn Company and later Pharmacia before co-founding a Contract Research Company, PharmOptima LLC in 2003. Patrick served as that company's CFO for 13 years before assuming his position at Cylerus, Inc.